

Ref. No.: WOCK/SEC/SE/2025-26/002

8th April, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/Madam,

Subject: Intimation for incorporation of a step-down subsidiary company

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland) Limited. Consequent to the incorporation, Wockhardt Antibiotics (Ireland) Limited has become a Step-Down Subsidiary of the Company.

The details required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1 /P/CIR/2023/123 dated July 13, 2023, are enclosed herewith as **Annexure A**. This intimation will also be available on the Company's Website at www.wockhardt.com

This is for your information and records.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary

Encls: A/a

Annexure - A

Details required under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No.	Particulars	Remarks
i.	Name of the target entity, details in brief such as size, turnover etc	Name: Wockhardt Antibiotics (Ireland) Limited Capital: 100 Euro divided into 100 shares of Euro 1 each Turnover: Not available as the entity is yet to commence business operations.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Not applicable. This intimation is towards incorporation of a step-down subsidiary of Wockhardt Limited.
3.	Industry to which the entity being acquired Belongs.	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Objects of Wockhardt Antibiotics (Ireland) Limited are in line with the main objects of the Company and the new entity will help to channelize the Company's antibiotic products across European Union.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Consideration in cash (through banking channel)
8.	Cost of acquisition and/or the price at which the shares are acquired	EUR 100 (100 shares were subscribed at EUR 1.0 per share).
9.	Percentage of shareholding / control acquired and /or number of shares acquired;	100% of the shares of Wockhardt Antibiotic (Ireland) Ltd is held by Wockhardt Bio AG which is a subsidiary of Wockhardt Ltd

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information.	<p>Wockhardt Antibiotics (Ireland) Limited is incorporated on 7th April, 2025 in Ireland as a step down subsidiary of the Company.</p> <p>Wockhardt Antibiotics (Ireland) Limited has not yet started its operations.</p>
-----	--	---